Mersana Therapeutics, Inc. (MRSN) Earnings History
Net Loss10 years of earnings data (2015–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Mersana Therapeutics, Inc. (MRSN) Earnings Overview
As of June 23, 2026, Mersana Therapeutics, Inc. (MRSN) reported trailing twelve-month net income of -$70M, reflecting +61.8% year-over-year growth. The company earned $-14.05 per diluted share over the past four quarters, with a net profit margin of -170.9%.
Looking at the long-term picture, MRSN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$14M in fiscal 2016.
Mersana Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), SNDX (-$243M net income, -165.6% margin), AGEN ($65M net income, 0.1% margin), MRSN has room to improve margins relative to the peer group. Compare MRSN vs RCUS →
MRSN Earnings vs Peers
Earnings metrics vs comparable public companies
MRSN Historical Earnings Data (2015–2024)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$69M | +59.7% | -$73M | $-14.12 | -170.9% | -181.1% |
| 2023 | -$172M | +15.9% | -$171M | $-36.96 | -465.8% | -463.9% |
| 2022 | -$204M | -20.1% | -$204M | $-54.51 | -768.3% | -766.6% |
| 2021 | -$170M | -93.2% | -$169M | $-60.24 | -395488.4% | -392693.0% |
| 2020 | -$88M | -212.1% | -$155M | $-35.80 | -10633.5% | -18737.4% |
| 2019 | -$28M | +56.1% | -$30M | $-16.21 | -67.0% | -71.7% |
| 2018 | -$64M | -66.0% | -$66M | $-69.75 | -606.5% | -619.7% |
| 2017 | -$39M | -182.5% | -$40M | $-42.95 | -220.6% | -225.8% |
| 2016 | -$14M | +16.6% | -$14M | $-19.58 | -54.4% | -54.9% |
| 2015 | -$16M | - | -$16M | $-23.48 | -158.6% | -157.7% |
Download Data
Export MRSN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MRSN — Frequently Asked Questions
Quick answers to the most common questions about buying MRSN stock.
What is MRSN earnings per share (EPS)?
MRSN trailing twelve-month (TTM) diluted EPS is $-14.05, reflecting +61.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2015 to 2024 is available in the table on this page.
What is Mersana Therapeutics, Inc.'s net income?
Mersana Therapeutics, Inc. (MRSN) trailing twelve-month net income is $-70M as of 2024. Earnings grew +61.8% year-over-year.
Is MRSN profitable?
MRSN is not currently profitable on a TTM basis, reporting a net loss of $-70M. Net margin is -170.9%. Investors should monitor for a return to profitability.
What is MRSN's earnings growth rate?
MRSN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2024.
What are MRSN's profit margins?
Mersana Therapeutics, Inc. net profit margin is -170.9%, operating margin is -181.1%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -505.1%.
Is MRSN growing earnings?
Yes, MRSN earnings are accelerating — EPS growth of +61.8% exceeds the 5-year CAGR of N/A. TTM net income reached $-70M. Earnings momentum is strengthening.
What was MRSN's best earnings year?
Mersana Therapeutics, Inc.'s highest annual net income on record is $-14M, achieved in fiscal year 2016. Earnings history on this page spans 2015 to 2024 and includes all annual and quarterly figures.
What were MRSN's earnings last quarter?
MRSN's most recent reported quarter was Q3 2025. Net income was $-8M with diluted EPS of $-1.51. For a full breakdown of all quarters, see the quarterly earnings table on this page.